Hair loss research developments in 2013
The most promising projects in the area of hair loss research today include development and testing of medications NEOSH101, bimatoprost, RK-023 and Avodart (dutasteride) as well as surgical techniques such as hair multiplication, also known as hair cloning, and hair generation in wounds of hair-free skin. Whereas the drugs NEOSH101, bimatoprost, RK-023 and Avodart give promise of replacing the currently most effective hair loss medications ...
A Quick Update on Bimatoprost Hair Loss Study
Bimatoprost, a glaucoma treatment that has been recently approved for lengthening and thickening eyelashes (Latisse) is currently being studied for its topical use in promoting hair growth in patients affected by hereditary hair loss. Preliminary reports from laboratory tests with human hair sound encouraging. It has been reported that...
Bosley Taking Over as the Market Leader in Hair Regeneration Research
Aderans Research Institute, an affiliate of Bosley and one of a few research units in the world involved in exploring hair regeneration (also known as hair cloning) has recently announced that it acquired the key research assets of its main competitor, Intercytex, one of the market leaders in the area of hair regeneration. This news was not unexpected as Bosley held an option...
Could Bimatoprost be the next FDA-Approved Medication for Hair Loss?
Bimatoprost, the main active ingredient of Allergan, a medication used to reduce intraocular pressure and thus control glaucoma, has been recently approved by the FDA for lengthening eyelashes. This new cosmetic formulation of bimatoprost is sold as Latisse...
Aderans's Hair Regeneration Project Entered Phase II Clinical Testing
Aderans, the main competitor of the financially-struggling market leader in the area of hair regeneration, Intercytex, has recently launched a Phase II clinical study on cell-based hair regeneration for men and women. Hair regeneration, also known as hair multiplication, hair cloning or follicular neogenesis...
Intercytex Facing Serious Financial Difficulties
Skin regeneration specialist Intercytex put itself up for sale following the failure of a Phase III study of its leading project involving Cyzact, a therapy for healing chronic wounds caused by venous leg ulcers. This failure, combined with poor economic results in 2008, leaves the company struggling to secure financing for its existing projects.
Telomerase a New Fountain of Youth?
Telomerase is an enzyme that adds specific DNA sequence repeats to the end of DNA strands in the telomere regions. Telomerase consists of two molecules each - telomerase reverse transcriptase (TERT), telomerase RNA (TERC) and dyskerin. By using TERC, TERT can add a specific six-nucleotide repeating sequence to the strand of chromosomes. These repeats are called telomeres.
Intercytex Reports Further Progress
In March 2008, Intercytex reported the latest results on its progress in the phase II clinical study of ICX-TRC. ICX-TRC is a suspension of a patient’s own dermal papilla cells that is injected into the patient scalp to stimulate new hair growth. Intercytex is a frontrunner in the development of hair multiplication. The latest results are consistent with the earlier data...
Intercytex Making Progress
Hair multiplication may be the next big step in surgical hair restoration. Several medical teams on three continents are currently researching hair multiplication. The UK-based firm Intercytex appears to be the frontrunner. Their latest report on the Phase II clinical study of ICX-TRC...
Generating New Hair Follicles
Follica, a US-based medical device company, is developing a novel approach that consists in generating completely new hair follicles in wounds of hair-free skin. This technique was licensed from the University of Pennsylvania. Researchers studying skin healing processes at the university noticed that new hair follicles formed in the middle of some wounds...
NEOSH101 Phase IIb Results Are Pending
NEOSH101 is a proteasome inhibitor (a potential osteoporosis cure), being presently developed into a hair loss remedy by the dermatology-focused specialty pharmaceutical company called Neosil. It is currently undergoing Phase IIb clinical trials for its targeted FDA approval conducted in Germany...